Avacta Announces Distribution Agreement With ABCAM plc

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Groups recently developed SARS-CoV-2 research ELISA Affimer reagents.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, April 6, 2021
Information
Tags: 
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Sarbecovirus, Affimer, Abcam, Zoonoses, Severe acute respiratory syndrome coronavirus, Branches of biology
Geotags: 
United Kingdom, Europe
Summary
Key Points: 
  • Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Groups recently developed SARS-CoV-2 research ELISA Affimer reagents.
  • ABCAM is one of the worlds leading suppliers of high-quality biological reagents and kits which are used in a wide range of fields including drug discovery, diagnostics and basic research.
  • Under the worldwide, non-exclusive distribution agreement, ABCAM will enable the global research community to access Avactas SARS-CoV-2 spike protein Affimer research reagents through its on-line catalogue.
  • Dr Alastair Smith, Chief Executive of Avacta Group commented: We are delighted that we have established a global route to market for the SARS-CoV-2 spike protein Affimer reagents through ABCAMs dedicated global commercialisation infrastructure.


Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.

Avacta has developed Affimer® reagents which can be used in a high performance ELISA laboratory test to detect the SARS-CoV-2 spike protein with high sensitivity and excellent specificity for the spike protein of the original strain of the virus and other dominant variants such as B117 (“Kent” strain) and D614G.

ABCAM is one of the world’s leading suppliers of high-quality biological reagents and kits which are used in a wide range of fields including drug discovery, diagnostics and basic research. Under the worldwide, non-exclusive distribution agreement, ABCAM will enable the global research community to access Avacta’s SARS-CoV-2 spike protein Affimer® research reagents through its on-line catalogue. This will allow scientists around the world to perform the ELISA test in their own laboratories and support the global fight against the pandemic.

Dr Alastair Smith, Chief Executive of Avacta Group commented: “We are delighted that we have established a global route to market for the SARS-CoV-2 spike protein Affimer® reagents through ABCAM’s dedicated global commercialisation infrastructure.

As far as we are aware, our spike protein ELISA test is the most sensitive test of its kind and, in ABCAM, we have a world-leading partner capable of maximising the commercial potential of the Affimer® reagents by making them globally available to scientists who are researching into the SARS-CoV-2 coronavirus.

I look forward to further updating the market on progress across the Group in due course.”

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

Copyright: 
Copyright Business Wire 2021